What type of study is this?

This is a Cohort Study study (also classified as: Human Clinical Trial).

What question did this study set out to answer?

To evaluate the efficacy and toxicity of loncastuximab tesirine in patients with relapse/refractory DLBCL and FL.

December 8, 2025BloodOpen Access

Evaluation of outcomes and toxicities of loncastuximab tesirine (Lonca) in relapse/refractory (R/R) diffuse large B-cell lymphoma (DLBCL) and follicular lymphoma (FL): Real-world data analysis (RWDA) from 10 US academic centers

View Full Paper

Ask AI

Bookmark

Authors

AHAlan D. HutsonRoswell Park Comprehensive Cancer Center JPJoseph F. ParkerUniversity of Manchester MMMuhamad Alhaj MoustafaWinnMed

Discussion

Member takes

Implication

Real-world data analysis shows loncastuximab tesirine improves survival in R/R diffuse large B-cell lymphoma, highlighting therapy response and adverse events.

Key Points

To evaluate the efficacy and toxicity of loncastuximab tesirine in patients with relapse/refractory DLBCL and FL.
Multicenter retrospective study of patients receiving loncastuximab tesirine from 2017 to 2025.
Assessment of demographic, pathological, treatment data, and adverse events was performed.
Efficacy outcomes included overall response rate, complete response, and survival analysis.
Median progression-free survival was 2.6 months and median overall survival was 6.7 months for the entire cohort.
The overall response rate was 37.7% for DLBCL and 49.4% for FL, with notable adverse events in 84% of patients.
No significant difference in overall survival was observed when comparing patients who received prior therapies.

Cite This Study

Hutson et al. (2025) studied this question.

synapsesocial.com/papers/69362f3d4fa91c937236d4d1 https://doi.org/10.1182/blood-2025-4514

View Full Paper

Ask AI

Bookmark

Implication

Real-world data analysis shows loncastuximab tesirine improves survival in R/R diffuse large B-cell lymphoma, highlighting therapy response and adverse events.

Evaluation of outcomes and toxicities of loncastuximab tesirine (Lonca) in relapse/refractory (R/R) diffuse large B-cell lymphoma (DLBCL) and follicular lymphoma (FL): Real-world data analysis (RWDA) from 10 US academic centers

Discussion

Member takes

Implication

Key Points

Cite This Study

Evaluation of outcomes and toxicities of loncastuximab tesirine (Lonca) in relapse/refractory (R/R) diffuse large B-cell lymphoma (DLBCL) and follicular lymphoma (FL): Real-world data analysis (RWDA) from 10 US academic centers

Discussion

Member takes

Implication

Key Points

Cite This Study

Also Consider

Also Consider